These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 30171052)

  • 1. Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.
    Wang Z; Zhao J; Wang G; Zhang F; Zhang Z; Zhang F; Zhang Y; Dong H; Zhao X; Duan J; Bai H; Tian Y; Wan R; Han M; Cao Y; Xiong L; Liu L; Wang S; Cai S; Mok TSK; Wang J
    Cancer Res; 2018 Nov; 78(22):6486-6496. PubMed ID: 30171052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
    Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
    Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
    Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.
    Wang HY; Deng L; Li YQ; Zhang X; Long YK; Zhang X; Feng YF; He Y; Tang T; Yang XH; Wang F
    Cancer Res Treat; 2021 Oct; 53(4):973-982. PubMed ID: 33677848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.
    Jia Q; Wang J; He N; He J; Zhu B
    JCI Insight; 2019 May; 4(10):. PubMed ID: 31092729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
    Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
    Acta Pharm Sin B; 2021 Oct; 11(10):2983-2994. PubMed ID: 34729299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
    Wu S; Zhang Y; Zhang Y; Chen LH; Ouyang HF; Xu X; Du Y; Ti XY
    Cancer Med; 2023 Feb; 12(4):4486-4495. PubMed ID: 36053931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.
    Takamochi K; Takahashi F; Suehara Y; Sato E; Kohsaka S; Hayashi T; Kitano S; Uneno T; Kojima S; Takeuchi K; Mano H; Suzuki K
    Lung Cancer; 2017 Aug; 110():26-31. PubMed ID: 28676214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Base excision repair regulates PD-L1 expression in cancer cells.
    Permata TBM; Hagiwara Y; Sato H; Yasuhara T; Oike T; Gondhowiardjo S; Held KD; Nakano T; Shibata A
    Oncogene; 2019 Jun; 38(23):4452-4466. PubMed ID: 30755733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
    Duffy MJ; Crown J
    Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging big data of immune checkpoint blockade response identifies novel potential targets.
    Bareche Y; Kelly D; Abbas-Aghababazadeh F; Nakano M; Esfahani PN; Tkachuk D; Mohammad H; Samstein R; Lee CH; Morris LGT; Bedard PL; Haibe-Kains B; Stagg J
    Ann Oncol; 2022 Dec; 33(12):1304-1317. PubMed ID: 36055464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
    Zheng M
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances and prospects of biomarkers for immune checkpoint inhibitors.
    Yamaguchi H; Hsu JM; Sun L; Wang SC; Hung MC
    Cell Rep Med; 2024 Jul; 5(7):101621. PubMed ID: 38906149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.